The intricate pathophysiology of intracerebral hemorrhage (ICH) presents significant challenges for therapeutic development, requiring preclinical models that accurately replicate key disease mechanisms including hematoma expansion, neuronal cell death, oxidative stress, blood-brain barrier disruption, and neuroinflammation. Ace Therapeutics addresses these challenges through a comprehensive portfolio of customized hemorrhagic stroke models and CRO services designed to support diverse research objectives from high-throughput screening to preclinical efficacy testing.
The company's in vitro ICH models simplify complex biological systems while retaining critical disease-relevant features, making them ideal for targeted pathway research. Hemoglobin models reliably reflect hematoma expansion and enable studies on iron dynamics and hemoglobin proteolysis, while hemin models mimic core secondary injury pathways such as BBB disruption and neuroinflammation. Autologous blood models replicate the full hemotoxicity of ICH, providing a physiologically relevant platform for studying blood-induced brain injury. Each model is optimized to address distinct research questions, allowing researchers to isolate and analyze targeted mechanisms without confounding variables.
As an experienced ICH animal model CRO, Ace Therapeutics offers a comprehensive suite of animal models across multiple species, including rodents and large-animal models tailored to match the translational needs of each study. Whole blood injection models serve as a gold standard for mimicking acute hematoma accumulation, allowing precise control of hematoma volume and evaluation of interventions for swelling, hematoma expansion, and hemodynamic changes. These models are applied in both small animals through rat or mouse caudate nucleus injections and large animals through pig or sheep frontal lobe or basal ganglia injections, closely replicating clinical ICH's rapid blood accumulation.
Collagenase models induce localized hemorrhage via microvascular rupture and offer flexibility in hematoma size control through dosage adjustment, making them suitable for studying both parenchymal and intraventricular hemorrhage. Microballoon insertion models simulate the space-occupying effects of ICH, replicating increased intracranial pressure and reduced cerebral blood flow—critical contributors to acute brain injury. The company's team collaborates with researchers to select optimal models aligned with study goals, whether focusing on acute versus chronic hematoma phases, molecular versus hemodynamic analysis, or efficacy testing of novel therapeutics.
This research matters because hemorrhagic stroke represents a significant global health burden with limited treatment options and devastating neurological consequences. The development of accurate preclinical models directly impacts the pace of therapeutic discovery by enabling researchers to study disease mechanisms in controlled environments that closely mimic human pathology. By providing customized hemorrhagic stroke models that bridge the gap between preclinical research and clinical application, Ace Therapeutics empowers the research community to overcome barriers in drug development. The implications extend to biotech companies, pharmaceutical firms, and academic researchers who can leverage these specialized tools to accelerate the translation of laboratory findings into potential life-saving treatments, ultimately reducing the global burden of hemorrhagic stroke through more efficient and targeted research approaches.
